CytomX Q1 revenue $50.9M; CX-2051 Phase 1 shows 28% ORR in advanced CRC

CytomX Therapeutics, Inc.

Q1 revenue $50.9M (up from $41.5M); operating expense $28.3M; cash $79.9M.
CX-2051 Phase 1: 28% ORR (5/18 confirmed PRs), 94% DCR, median PFS 5.8 months in advanced CRC.
Dose expansions started at 7.2, 8.6, 10 mg/kg Q3W; Phase 2 planned 1H 2026.
Astellas milestone $5M; cash runway into Q2 2026.
CX-801 Phase 1a data in melanoma expected 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.